ARWR Arrowhead Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARWR

Price (delayed)

$63.18

Market cap

$6.58B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.07

Enterprise value

$6.23B

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger ...

Highlights
The company's revenue fell by 36% YoY but it rose by 12% QoQ
The gross profit is down by 36% YoY but it is up by 12% QoQ
The quick ratio has plunged by 72% from the previous quarter and by 40% YoY
Arrowhead Pharmaceuticals's debt has surged by 60% YoY and by 14% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://arrowheadpharma.com
Peers: ALNY DRNA LGND INO

Key stats

What are the main financial stats of ARWR
Market
Shares outstanding
104.08M
Market cap
$6.58B
Enterprise value
$6.23B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
14.72
Price to sales (P/S)
73.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
69.88
Earnings
Revenue
$89.12M
EBIT
-$116.37M
EBITDA
-$109.29M
Free cash flow
$165.21M
Per share
EPS
-$1.07
Free cash flow per share
$1.59
Book value per share
$4.29
Revenue per share
$0.86
TBVPS
$7.15
Balance sheet
Total assets
$756.8M
Total liabilities
$311.25M
Debt
$23.8M
Equity
$445.55M
Working capital
$419.57M
Liquidity
Debt to equity
0.05
Current ratio
3.51
Quick ratio
3.46
Net debt/EBITDA
3.19
Margins
EBITDA margin
-122.6%
Gross margin
100%
Net margin
-123%
Operating margin
-132.8%
Efficiency
Return on assets
-18.8%
Return on equity
-23.6%
Return on invested capital
-38.5%
Return on capital employed
-19.7%
Return on sales
-130.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARWR stock price

How has the Arrowhead Pharmaceuticals stock price performed over time
Intraday
-0.75%
1 week
-1.27%
1 month
4.14%
1 year
38.1%
YTD
-17.66%
QTD
-23.71%

Financial performance

How have Arrowhead Pharmaceuticals's revenue and profit performed over time
Revenue
$89.12M
Gross profit
$89.12M
Operating income
-$118.35M
Net income
-$109.59M
Gross margin
100%
Net margin
-123%
The company's revenue fell by 36% YoY but it rose by 12% QoQ
The gross profit is down by 36% YoY but it is up by 12% QoQ
The net income has declined by 7% since the previous quarter
The operating margin has increased by 6% since the previous quarter

Growth

What is Arrowhead Pharmaceuticals's growth rate over time

Valuation

What is Arrowhead Pharmaceuticals stock price valuation
P/E
N/A
P/B
14.72
P/S
73.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
69.88
ARWR's EPS is down by 6% from the previous quarter
The price to book (P/B) is 79% higher than the 5-year quarterly average of 8.3 and 16% higher than the last 4 quarters average of 12.8
The equity has contracted by 10% YoY
The price to sales (P/S) is 60% less than the 5-year quarterly average of 184.4 but 14% more than the last 4 quarters average of 65.2
The company's revenue fell by 36% YoY but it rose by 12% QoQ

Efficiency

How efficient is Arrowhead Pharmaceuticals business performance
The company's return on equity fell by 9% QoQ
Arrowhead Pharmaceuticals's return on invested capital has decreased by 8% QoQ
ARWR's ROS is up by 4.7% from the previous quarter
The company's return on assets rose by 2.1% QoQ

Dividends

What is ARWR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARWR.

Financial health

How did Arrowhead Pharmaceuticals financials performed over time
ARWR's total assets is 143% higher than its total liabilities
The company's current ratio has shrunk by 73% QoQ and by 41% YoY
The quick ratio has plunged by 72% from the previous quarter and by 40% YoY
Arrowhead Pharmaceuticals's debt is 95% lower than its equity
The debt to equity has soared by 67% YoY
Arrowhead Pharmaceuticals's debt has surged by 60% YoY and by 14% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.